Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Chlamydia Infections - Overview Chlamydia Infections - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Chlamydia Infections - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Chlamydia Infections - Companies Involved in Therapeutics Development Abera Bioscience AB Abivax SA Evofem Biosciences Inc Genetic Immunity Inc Lead Discovery Center GmbH Merck & Co Inc NanoBio Corp Prokarium Ltd QureTech Bio AB SATT IDF Innov SAS Selecta Biosciences Inc SIGA Technologies Inc Vault Pharma Inc Vaxine Pty Ltd Chlamydia Infections - Drug Profiles Ab-03 - Drug Profile Product Description Mechanism Of Action R&D Progress ABX-196 - Drug Profile Product Description Mechanism Of Action R&D Progress Amphora - Drug Profile Product Description Mechanism Of Action R&D Progress ChlamyDerm - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia trachomatis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia trachomatis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress PEG-2S - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Chlamydia Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile Product Description Mechanism Of Action R&D Progress solithromycin - Drug Profile Product Description Mechanism Of Action R&D Progress ST-669 - Drug Profile Product Description Mechanism Of Action R&D Progress VPI-201 - Drug Profile Product Description Mechanism Of Action R&D Progress Chlamydia Infections - Dormant Projects Chlamydia Infections - Product Development Milestones Featured News & Press Releases Apr 20, 2017: New weapon in fight against antibiotic resistance discovered Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Chlamydia Infections, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Universities/Institutes, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2018 Chlamydia Infections - Pipeline by Abivax SA, H1 2018 Chlamydia Infections - Pipeline by Evofem Biosciences Inc, H1 2018 Chlamydia Infections - Pipeline by Genetic Immunity Inc, H1 2018 Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H1 2018 Chlamydia Infections - Pipeline by Merck & Co Inc, H1 2018 Chlamydia Infections - Pipeline by NanoBio Corp, H1 2018 Chlamydia Infections - Pipeline by Prokarium Ltd, H1 2018 Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2018 Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H1 2018 Chlamydia Infections - Pipeline by Selecta Biosciences Inc, H1 2018 Chlamydia Infections - Pipeline by SIGA Technologies Inc, H1 2018 Chlamydia Infections - Pipeline by Vault Pharma Inc, H1 2018 Chlamydia Infections - Pipeline by Vaxine Pty Ltd, H1 2018 Chlamydia Infections - Dormant Projects, H1 2018List of Figures Number of Products under Development for Chlamydia Infections, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018